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Abstract: Atopic dermatitis (AD) is a common, chronic, relapsing, severely pruritic, eczematous 
skin disease. The mainstays of treatment for AD are topical tacrolimus and topical steroids. 
Tacrolimus, a calcineurin inhibitor, not only complements existing treatment options but also 
overcomes some of the drawbacks of topical steroid therapy when given topically and thus 
meets the long-term needs of patients in preventing disease progression. Topical tacrolimus 
has been widely recognized in terms of its short- and long-term efficacies and safety, and it 
is also accepted as a first-line treatment for inflammation in AD. The recent proactive use of 
topical tacrolimus may emphasize a long-term benefit of this calcineurin inhibitor for AD 
treatment. To reduce possible long-term adverse effects, it is important to monitor its topical 
doses in daily clinics.
Keywords: atopic dermatitis, topical tacrolimus, topical steroids, dose, proactive use, adverse 
effects
Introduction
Atopic dermatitis (AD) is a common, chronic or chronically relapsing, severely 
pruritic, eczematous skin disease. In our previous Kyushu University Ishigaki Atopic 
Dermatitis Study cohort, 71.6% of AD patients regressed spontaneously, whereas 
5.5% of non-AD individuals developed AD among nursery school children during 
the 3-year follow-up.1 The incidence rate of AD in Japanese elementary school stu-
dents was approximately 3% from 1981 to 1983, but increased to about 6% to 7% in 
the 1990s.2 In recent years, the percentage of adolescent- and adult-type AD has also 
been increasing.3 As the first-line therapy for AD in Japan, topical steroids, topical 
tacrolimus and emollients are the mainstays in addition to oral antihistamines, but not 
topical pimecrolimus which is unavailable in Japan. The purpose of this article is to 
review recent research on topical tacrolimus as a treatment for AD.
Impact of topical tacrolimus  
on topical steroid therapy
The clinical usefulness of topically active corticosteroids must be judged in the light 
of their anti-inflammatory activity and propensity to cause undesirable local side 
effects, as well as their systemic side effects from absorption through the skin. Topical 
corticosteroids are generally used for patients with AD of variable clinical severity. 
When the disease is severely exacerbated, it is likely that patients use more creams and 
ointments than when it is under reasonable control. Although their frequency is low, 
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sites, such as telangiectasia, skin atrophy, hypertrichosis, 
perioral dermatitis, fungal/bacterial/viral infection and 
atrophic cutaneous striae;4,5 these side effects have long 
been known. On the other hand, the efficacy and safety of 
topical corticosteroids when used appropriately are also well-
recognized.6,7 However, it is not uncommon for patients to 
express irrational fear and anxiety regarding the use of topical 
corticosteroids.7,8 This ‘steroid phobia’ may be accentuated 
by media publicity as well as by the common misconception 
that topical corticosteroids are analogous to anabolic steroids 
or oral steroids. Moreover, physician’s and/or pharmacist’s 
advice to apply topical corticosteroids ‘sparingly’ or ‘thinly’ 
with accompanying messages to exercise caution against 
steroid adverse effects usually influences patients to interpret 
such warnings negatively, giving rise to steroid phobia which 
causes poor adherence to treatment.9 Experience in dermatol-
ogy outpatient clinics has suggested that many patients are 
reluctant to use even mild topical corticosteroids, which may 
have important implications in terms of patient compliance 
and subsequent response to treatment.7
Before topical tacrolimus was commercially available 
in Japan, we collected clinical data from 1271 AD patients 
(210 infantile, 546 childhood, and 515 adolescent and adult 
AD) who had been followed for at least 6 months in outpa-
tient clinics.5 All of the patients were treated with topical 
steroids and moisturizing emollients. The clinical severity 
of AD in the majority of the patients improved or remained 
unchanged after 6 months of conventional therapy. However, 
19% of the adolescent and adult AD patients remained in 
a very severe or severe state or experienced exacerbation 
(‘uncontrolled’ group).5 After topical tacrolimus became 
commercially available in Japan in 1999, we collected clini-
cal data from 215 patients with adolescent- and adult-type 
AD who had been followed by topical tacrolimus and steroid 
combination for at least 6 months in outpatient clinics.10 Very 
interestingly, the clinical severity of AD improved remarkably 
in the majority of the patients after 6 months of combination 
topical therapy. Only 6% of the patients with adolescent- and 
adult-type AD showed uncontrolled disease.10 In addition, a 
reduction in the dose of the topical steroid by add-on tacroli-
mus application clearly attenuated the incidence and intensity 
of steroid-induced side effects.10,11
Clinical effects of topical  
tacrolimus on AD
Recent meta-analysis studies have shown the clinical efficacy 
of topical tacrolimus against AD.12,13 El-Batawy et al reported 
the results of meta-analysis from 10 papers on randomized 
control trials involving 2771 topical tacrolimus-treated 
patients and 2824 controls.13 It was demonstrated that topical 
tacrolimus was significantly more effective than the vehicle. 
Compared with topical steroids, both 0.1% and 0.03% 
tacrolimus ointments were as effective as moderate potency 
steroids, and more effective than a combined steroid regi-
men. Also, tacrolimus was more effective than mild steroids. 
Chronic AD lesions of the face and flexures are the most 
justified indications for topical tacrolimus.13
In 2 randomized, double-blind studies of 632 adults 
with AD, Hanifin et al reported that patients treated with 
0.1% and 0.03% tacrolimus ointment showed significantly 
greater improvement than those treated with the vehicle for 
all efficacy parameters evaluated, including the percentage 
body surface area affected, the total score and individual 
scores for signs of AD, the patient’s assessment of pruritus, 
and Eczema Area and Severity Index (EASI) score.14 
Specifically, the 0.1% concentration was more effective 
than the 0.03% concentration.14 Although tacrolimus is a 
very potent immunosuppressant, its clinical potency remains 
limited because of its low transepidermal absorption. When 
applied for 1 week, 0.1% tacrolimus ointment was shown 
to be more potent than 0.1% alclomethasone dipropionate 
ointment.15 Both 0.03% and 0.1% tacrolimus ointments 
were significantly more effective than 1% hydrocortisone 
acetate when applied for 3 weeks in children.16 The efficacy 
of 0.1% tacrolimus ointment was similar to that of 0.1% 
hydrocortisone butyrate ointment and 0.12% betamethasone 
valerate ointment when applied for 3 weeks in adults.17,18 
The continuous efficacy of topical tacrolimus has been con-
firmed in a previous long-term study, in which marked or 
excellent improvement or clearance of disease was reported 
in 54%, 81%, and 86% of patients at week 1, month 6, and 
month 12, respectively.19 Adverse events such as burning 
sensation (47% of patients) were common but tended to 
occur only when initiating treatment.19 In a 2-year long-term 
application trial, marked or excellent improvement or clear-
ance of disease was reported in 90% and 93.1% of patients 
at weeks 10 and 104, respectively.20 Adverse events such as 
burning sensation occurred in 79.2% (450/568) of patients 
within 1 year; however, the incidence of irritation side effects 
decreased to only 5.5% (23/418) of patients who applied the 
ointment for more than 1 year.20 Similar short-term and long-
term efficacies of topical tacrolimus were previously reported 
in children with AD.21–25 Taken together, the important find-
ing is that the efficacy of topical tacrolimus is not attenuated 
under long-term continuous application for at least 2 years. 
The blood concentration of absorbed tacrolimus is very low Clinical, Cosmetic and Investigational Dermatology 2009:2 163
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and usually does not exceed 3 ng/mL (most patients are below 
the detection limit of 0.5 ng/mL).
Adverse effects of topical 
tacrolimus
The most common adverse events induced by topical tacro-
limus are sensation of skin burning or irritation, especially 
among patients with severe or extensive disease. However, 
these events are usually brief and resolve during the first few 
days of treatment.26 Unlike topical corticosteroids, topical 
tacrolimus does not cause skin atrophy.27
Bacterial and viral infections are commonly associ-
ated with AD.28,29 As tacrolimus is an immunosuppressive 
drug, topical tacrolimus therapy may potentially increase 
the risk of cutaneous infections. However, Fleischer et al 
reported that treatment of AD with tacrolimus ointment 
was not associated with an increase in cutaneous infec-
tions.30 A systematic review of 1554 AD patients treated 
with tacrolimus ointment in 5 clinical trials revealed that the 
12-week adjusted incidence rates of all cutaneous infections 
in patients treated with the vehicle, 0.03% tacrolimus oint-
ment, and 0.1% tacrolimus ointment were 18.0%, 24.8%, 
and 17.7% for adult patients, and 20.9%, 19.6%, and 23.6% 
for pediatric patients, respectively.30 The incidence of any 
individual cutaneous infection in the tacrolimus group was 
not significantly higher than that in the vehicle group, with 
the exception of folliculitis in adults.30 Several other reports 
also supported these findings.5,10,31,32 One of the major con-
cerns in topical tacrolimus therapy in AD patients is the pos-
sible increase in herpes infection and subsequent Kaposi’s 
varicelliform eruption; however, recent long-term studies 
have clearly demonstrated that topical tacrolimus does not 
increase herpes infection.31,32
In March 2005, the Food and Drug Administration (FDA) 
issued a public health advisory informing healthcare profes-
sionals and patients about the potential risk of developing 
cancer from the use of topical calcineurin inhibitors (http://
www.fda.gov/bbs/topics/ANSWERS/2005/ANS01343.
html). This concern is based on information from animal 
studies, case reports in a small number of patients, and 
knowledge of how drugs in this class work. Specifically, 
in an issued statement, the FDA concluded that it may take 
10 years or longer in human studies to determine if the use 
of topical calcineurin inhibitors is linked to cancer develop-
ment. Very recently, Arellano et al have investigated the 
association between topical immunosuppressant therapy and 
development of lymphoma in 293,253 patients and found 
no increased risk of lymphoma in those treated with topical 
calcineurin inhibitors.33 Moreover, Margolis et al found no 
association between exposure to topical calcineurin inhibitors 
and an increased risk of non-melanoma skin cancers in 5000 
adults with dermatitis.34
Irrational fear of drugs always hampers patients’ adher-
ence and compliance to therapy. McNeill and Koo stated that 
animal and human studies suggest that topical tacrolimus 
is a safe alternative to topical steroids, with only transient 
burning sensation as the major known adverse effect com-
pared with those of topical steroids, including long-term 
side effects.35 Therefore, currently available data do not 
suggest that ‘unknown risks’ of topical tacrolimus need be 
any more concerning than the known side-effects of the 
topical steroids.35
Recent topics on topical tacrolimus
Fleischer et al compared the efficacy and safety of 0.1% 
tacrolimus ointment and 1% pimecrolimus cream in adult 
patients with moderate to very severe AD. In their study, 
281 patients (141 treated with tacrolimus and 140 treated 
with pimecrolimus) were randomized to a multicenter, 
investigator-blinded, 6-week study. Tacrolimus-treated 
patients had significantly greater improvements in EASI 
score than pimecrolimus-treated patients (mean % reduction 
from baseline to study end: 57% vs 39%, respectively; 
P = 0.0002). Treatment success rate was also significantly 
higher among the tacrolimus-treated patients than among 
the pimecrolimus-treated patients (40% vs 22% at study 
end; P = 0.001), as well as improvement in the percentage 
of total body surface area affected (a reduction of 49% vs 
34% at study end; P = 0.01).36
With regard to itch sensation, Hon et al evaluated the 
clinical efficacy of topical tacrolimus for itch reduction in 
children with AD. Seven children (3  and 4 girls) with AD 
were treated with topical tacrolimus for a consecutive 2-week 
period after a 1-week run-in. The clinical severity of AD was 
assessed using the SCORing Atopic Dermatitis scale. Sleep 
disturbance, as reported by the patients, and nocturnal scratch-
ing documented by a wrist movement monitor (DigiTrac), 
were evaluated at baseline and throughout treatment. Itch and 
sleep disturbance scores were reduced. Moreover, scratching 
activity, as documented by the DigiTrac movement recorder, 
was reduced from 115.0 g/min (64.8–215.5) to 71.5 g/min 
(51.0–118.0) (P = 0.028) after 2 weeks of treatment, showing 
that tacrolimus is effective in relieving itch in children with 
AD.37 In another study, the efficacy and safety of tacrolimus 
ointment for pediatric patients with AD was evaluated by 
meta-analysis.38 In this previous study, topical tacrolimus Clinical, Cosmetic and Investigational Dermatology 2009:2 164
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induced remission of pediatric AD, and the effects of 0.03% 
and 0.1% tacrolimus ointment were better than those of 1% 
hydrocortisone acetate and 1% pimecrolimus. However, 
no significant difference was found between the 0.03% 
tacrolimus group and the 0.1% tacrolimus group.
The long-term safety of topical tacrolimus was previ-
ously assessed by Remitz et al39 using an open-label study, 
with the incidence of adverse events being the primary 
end-point. In the study, 466 children with AD aged 
2 to 15 years applied 0.03% or 0.1% tacrolimus ointment 
twice daily for up to 29.5 months. The most common 
application site events were skin burning and pruritus, but 
their prevalence decreased over time. There was no increase 
in viral infections or other adverse events over time, and 
laboratory profiles were consistent with those reported in 
atopic populations. Substantial improvement in all efficacy 
end-points was observed by week 2 and was maintained 
throughout the study.39 Reitamo et al conducted a 4-year 
follow-up study of AD therapy with 0.1% tacrolimus oint-
ment where both children and adults applied the ointment 
continuously or intermittently twice daily during episodes 
of active disease plus an additional week after remission 
over a follow-up period of up to 4 years.40 The intent-to-treat 
population comprised 782 patients (median age, 22 years; 
range 2–72) who remained in the study for up to 4 years. 
Approximately half of the patients discontinued the study 
prematurely; the median follow-up period was 1422 days. 
The median tacrolimus ointment use during the first week 
was 31.2 g, and ointment use decreased during the first year 
and then remained stable for the remainder period of the 
study. The median cumulative tacrolimus use was 271.5 g at 
month 6, 462.5 g at month 12, 739.9 g at month 24, 1029.3 g 
at month 36 and 1320.8 g at month 48. Altogether 51.8% 
of the patients discontinued prematurely and the main rea-
sons were withdrawal of consent (13.3%), loss to follow-up 
(11.3%) and lack of efficacy (9.4%). Adverse events led to 
discontinuation in 3.7% of the patients. The most frequent 
application site events were skin burning and pruritus most 
commonly occurring in adult patients during the initial treat-
ment period; prevalence decreased after the first week and 
remained at a low level throughout the study. In general, cal-
culated daily hazard rates showed no indication of increased 
risk of adverse events with prolonged treatment. The total 
affected body surface area decreased substantially upon 
treatment onset, and treatment efficacy was maintained until 
the end of the study with smaller but continuous improve-
ments throughout the follow-up period. Overall, 75% of the 
patients and 76% of the investigators rated their satisfaction 
with the treatment as excellent, very good or good at the end 
of the study or at the time of premature discontinuation. The 
safety profile of the intermittent or continuous long-term 
application of 0.1% tacrolimus ointment for up to 4 years 
was consistent with that established from shorter studies and 
implied no cause for concern. In addition, 0.1% tacrolimus 
ointment demonstrated sustained efficacy as reflected by the 
expression of high satisfaction with the treatment by both 
patients and investigators.40 In another study, the long-term 
safety of tacrolimus was evaluated by Krueger et al who 
reviewed its pharmacokinetics after topical application in 
adult and pediatric patients with moderate to severe AD 
from all clinical trials in which tacrolimus blood levels were 
obtained.41 In their study, 0.03% or 0.1% tacrolimus ointment 
was applied twice daily. During the 12 clinical efficacy trials 
of tacrolimus ointment, single blood samples were obtained 
at various times relative to tacrolimus ointment application. 
In the pharmacokinetic studies, the concentration of 89% to 
95% of tacrolimus whole blood samples was 1 ng/mL; the 
mean maximum concentrations ranged from 0.2 to 1.6 ng/mL 
and the mean area under the blood concentration-time curves 
(0–12 hours) ranged from 1.4 to 13.1 ng × h/mL. Likewise, 
in the clinical efficacy trials, the concentration of the major-
ity (85%–99%) of tacrolimus samples was 1 ng/mL. 
Furthermore, Krueger et al showed that tacrolimus ointment 
is associated with minimal systemic absorption and no evi-
dence of systemic accumulation in patients with moderate 
to severe AD.41
One of the recent topics on topical tacrolimus is that 
proactive intermittent low-dose application can control acute 
disease and prevent exacerbations. For example, a 12-month 
European multicenter randomized study previously demon-
strated that the proactive, twice-weekly application of 0.03% 
tacrolimus ointment can maintain AD in remission and reduce 
the incidence of disease exacerbation (DE) in children with 
AD.42 During the initial open-label period, 267 children with 
AD applied 0.03% tacrolimus ointment twice daily for up to 
6 weeks to all affected areas. When an Investigator Global 
Assessment (IGA) score of 2 was achieved, the patient 
entered the disease control period (DCP) and was randomized 
to receive tacrolimus (n = 125) or vehicle ointment (n = 125) 
twice weekly for 12 months. Exacerbations were treated with 
0.03% tacrolimus ointment twice daily until an IGA  2 
was regained, then randomized treatment was restarted. The 
outcome measure was the number of DEs during the DCP 
that required substantial therapeutic intervention. Proactive 
application of 0.03% tacrolimus ointment significantly reduced 
the number of DEs during the DCP that required substantial Clinical, Cosmetic and Investigational Dermatology 2009:2 165
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therapeutic intervention and the percentage of DE treatment 
days, and increased the time to first DE requiring intervention.42 
Furthermore, similar beneficial clinical effects by this type of 
proactive treatment with 0.1% tacrolimus ointment have been 
reported in patients with adult AD.43
Breneman et al also evaluated the long-term efficacy 
and safety of 3-times-weekly use of tacrolimus ointment for 
preventing AD relapse.44 Adult and pediatric patients with 
moderate to severe AD who were clear of the disease after up 
to 16 weeks of treatment with tacrolimus ointment were ran-
domized in a double-blind fashion to 3-times-weekly treatment 
with either tacrolimus ointment (0.03% or 0.1%) or vehicle for 
40 weeks. The number of flare-free treatment days was con-
sidered as the primary end-point. A total of 125 patients were 
randomized to tacrolimus and 72 patients to vehicle. The mean 
number of flare-free treatment days was 177 for tacrolimus and 
134 for vehicle (P = 0.003). The median time to first relapse 
was 169 days for tacrolimus and 43 for vehicle (P = 0.037). 
Maintenance therapy with tacrolimus ointment was associated 
with significantly more flare-free days than vehicle treatment, 
as well as a significantly longer time until first relapse.44
Conclusions
The major side effect of topical tacrolimus is a transient burn-
ing sensation which usually subsides within several days of 
continuous application. Topical tacrolimus has already been 
commercially available for 10 years in Japan, and so far there 
have been no case reports on the development of internal and 
cutaneous malignancies due to topical tacrolimus. Topical 
tacrolimus is presently considered a safe and beneficial drug, 
and in conjunction with topical steroids, plays a major role in 
the management of AD. Careful follow-up and dose monitor-
ing are however essential in order to foster this life-changing 
drug in dermatology-related medical fields.
Acknowledgment
This work was partially supported by grants from the Ministry 
of Health, Labor and Welfare, Japan.
Disclosures
The authors disclose no conflicts of interest.
References
  1.  Fukiwake N, Furusyo N, Kubo N, et al. Incidence of atopic dermatitis in 
nursery school children – a follow-up study from 2001 to 2004, Kyushu 
University Ishigaki Atopic Dermatitis Study (KIDS). Eur J Dermatol. 
2006;16(4):416–419.
  2.  Takeuchi M, Ueda H. Increase of atopic dermatitis (AD) in recent Japan. 
Envir Dermatol. 2000;7(2):133–136.
  3.  Sugiura H, Umemoto N, Deguchi H, et al. Prevalence of childhood 
and adolescent atopic dermatitis in a Japanese population: Comparison 
with the disease frequency examined 20 years ago. Acta Dermato-
Venereologica. 1998;78(4):293–294.
  4.  Griffiths WAD, Wilkinson JD. Topical Therapy. In: Champion RH, 
Burton JL, Burns DA, Breathnach SM, eds. Textbook of Dermatology. 
6th ed. Oxford: Blackwell Scientific Publications; 1998:3519–3563.
  5.  Furue M, Terao H, Rikihisa W, et al. Clinical dose and adverse effects 
of topical steroids in daily management of atopic dermatitis. Br J 
Dermatol. 2003;148(1):128–133.
  6.  Surber C, Itin PH, Bircher AJ, et al. Topical corticosteroids. J Am Acad 
Dermatol. 1995;32(6):1025–1030.
  7.  Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in 
patients with atopic eczema. Br J Dermatol. 2000;142(5):931–936.
  8.  David TJ. Steroid scare. Arch Dis Child. 1987;62(9):876–878.
  9.  Bewley A. Dermatology Working Group. Expert consensus: time for a 
change in the way we advise our patients to use topical corticosteroids. 
Br J Dermatol. 2008;158(5):917–920.
10.  Furue M, Terao H, Moroi Y, et al. Dosage and adverse effects of topical 
tacrolimus and steroids in daily management of atopic dermatitis. 
J Dermatol. 2004;31(4):277–283.
11.  Japanese FK-506 Ointment Study Group. Long-term study of FK-506 
(Tacrolimus) ointment in patients with atopic dermatitis – Analysis at 
the time of 1-year observation. Rinsho Iyaku. 1998;14(10):2405–2432. 
[in Japanese].
12.  Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy 
and tolerability of topical pimecrolimus and tacrolimus in the treatment 
of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ. 
2005;330(7490):516.
13.  El-Batawy MM, Bosseila MA, Mashaly HM, Hafez VS. Topical 
calcineurin inhibitors in atopic dermatitis: a systematic review and 
meta-analysis. J Dermatol Sci. 2009;54(2):76–87.
14.  Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus 
ointment for the treatment of atopic dermatitis in adult patients: part I, 
efficacy. J Am Acad Dermatol. 2001;44(1 Suppl):S28–S38.
15.  Japanese FK-506 ointment study group. Phase III study of FK-506 
(Tacrolimus) ointment in patients with atopic dermatitis-Comparison 
study with 0.1% alclomethasone dipropionate ointment for facial and neck 
lesions-. Acta Dermatol (Kyoto). 1997;92(3):277–288. [in Japanese].
16.  Reitamo S, Van Leent EJ, Ho V , et al. Efficacy and safety of tacroli-
mus ointment compared with that of hydrocortisone acetate ointment 
in children with atopic dermatitis. J Allergy Clin Immunol. 2002; 
109(3):539–546.
17.  Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacro-
limus ointment compared with that of hydrocortisone butyrate oint-
ment in adult patients with atopic dermatitis. J Allergy Clin Immunol. 
2002;109(3):547–555.
18.  Japanese FK-506 Ointment Study Group. Phase III study of FK-506 
(Tacrolimus) ointment in patients with atopic dermatitis-Comparison 
study with 0.12% betamethasone valerate ointment for trunk and 
extremities lesions. Nishinihon J Dermatol. 1997;59(5):870–879. [in 
Japanese].
19.  Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year 
of tacrolimus ointment monotherapy in adults with atopic dermatitis. 
The European Tacrolimus Ointment Study Group. Arch Dermatol. 
2000;136(8):999–1006.
20.  Japanese FK-506 Ointment Study Group. Long-term study of FK-506 
(Tacrolimus) ointment in patients with atopic dermatitis – Analysis 
at the time of completion of 2-year observation. Rinsho Iyaku. 
2001;17(6):705–726. [in Japanese].
21.  Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, 
Hanifin JM. A randomized, vehicle-controlled trial of tacrolimus oint-
ment for treatment of atopic dermatitis in children. Pediatric Tacrolimus 
Study Group. J Allergy Clin Immunol. 1998;102(4 Pt 1):637–644.
22.  Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Long-term safety 
and efficacy of tacrolimus ointment for the treatment of atopic dermatitis 
in children. J Am Acad Dermatol. 2001;44(1 Suppl):S58–S64.Clinical, Cosmetic and Investigational Dermatology 2009:2
Clinical, Cosmetic and Investigational Dermatology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal
Clinical, Cosmetic and Investigational Dermatology is an interna-
tional, peer-reviewed, open access, online journal that focuses on 
the latest clinical and experimental research in all aspects of skin 
disease and cosmetic interventions. All areas of dermatology will 
be covered; contributions will be welcomed from all clinicians and 
basic science researchers globally. This journal is indexed on CAS. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. 
Visit http://www.dovepress.com/testimonials.php to read real quotes 
from published authors.
166
Furue and Takeuchi Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
23.  Otsuki M, Nakagawa H, Kawashima M, Shibata Y, Harada S. 
Japanese FK-506 Ointment Study Group. Efficacy and safety of 
FK506 (tacrolimus) ointment in children with atopic dermatitis-
phase III double-blinded comparison with vehicle ointment. Rinsho 
Iyaku. 2003;19(4):569–595. [in Japanese].
24.  Kawashima M, Otsuki M, Shibata Y, Harada S, Nakagawa H. Japanese 
FK-506 Ointment Study Group. Long-term study of FK506 (tacro-
limus) ointment in children with atopic dermatitis. Rinsho Iyaku. 
2003;19(4):597–636. [in Japanese].
25.  Otsuki M, Kawashima M, Harada S, Nakagawa H. Japanese FK-506 
Ointment Study Group. An extension study of FK-506 (tacrolimus) 
ointment as a follow-up to the double-blinded comparison study in 
children with atopic dermatitis. Rinsho Iyaku. 2005;21(3):335–360.
26.  Soter NA, Fleischer AB Jr, Webster GF, Monroe E, Lawrence I. Tacro-
limus ointment for the treatment of atopic dermatitis in adult patients: 
part II, safety. Am Acad Dermatol. 2001;44(1 Suppl):S39–S46.
27.  Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not 
affect collagen synthesis: results of a single-center randomized trial. 
J Invest Dermatol 1998;111(3):396–398.
28.  David TJ, Cambridge GC. Bacterial infection in atopic eczema. Arch 
Dis Child. 1986;61(1):20–23.
29  avid TJ, Longson M. Herpes simplex infection in atopic eczema. Arch 
Dis Child. 1985;60(4):338–343.
30.  Fleischer AB Jr, Ling M, Eichenfield L, et al. Tacrolimus ointment for 
the treatment of atopic dermatitis is not associated with an increase in 
cutaneous infections. J Am Acad Dermatol. 2002;47(4):562–550.
31.  Hashizume H, Yagi H, Ohshima A, et al. Comparable risk of herpes 
simplex virus infection between topical treatments with tacrolimus 
and corticosteroids in adults with atopic dermatitis. Br J Dermatol. 
2006;154(6):1204–1206.
32.  Reitamo S, Ortonne JP, Sand C, et al. European Tacrolimus Ointment 
Study Group. Long-term treatment with 0.1% tacrolimus ointment in 
adults with atopic dermatitis: results of a two-year, multicentre, non-
comparative study. Acta Derm Venereol. 2007;87(5):406–412.
33.  Arellano FM, Wentworth CE, Arana A, Fernández C, Paul CF. 
Risk of lymphoma following exposure to calcineurin inhibitors and 
topical steroids in patients with atopic dermatitis. J Invest Dermatol. 
2007;127(4):808–816.
34.  Margolis DJ, Hoffstad O, Bilker W. Lack of association between 
exposure to topical calcineurin inhibitors and skin cancer in adults. 
Dermatology. 2007;214(4):289–295.
35.  McNeill AM, Koo JY. “Unknown Risks” of non-steroid topical medica-
tions for atopic dermatitis. Int J Dermatol. 2007;46(6):656–658.
36.  Fleischer AB Jr, Abramovits W, Breneman D, Jaracz E. US/Canada 
tacrolimus ointment study group. Tacrolimus ointment is more effec-
tive than pimecrolimus cream in adult patients with moderate to very 
severe atopic dermatitis. J Dermatol Treat. 2007;18(3):151–157.
37.  Hon KL, Lam MC, Leung TF, Chow CM, Wong E, Leung AK. Assessing 
itch in children with atopic dermatitis treated with tacrolimus: objective 
versus subjective assessment. Adv Ther. 2007;24(1):2328.
38.  Yan J, Chen SL, Wang XL, Zhou W, Wang FS. Meta-analysis of 
tacrolimus ointment for atopic dermatitis in pediatric patients. Pediatr 
Dermatol. 2008;25(1):117–120.
39.  Remitz A, Harper J, Rustin M, et al. Long-term safety and efficacy of 
tacrolimus ointment for the treatment of atopic dermatitis in children. 
Acta Derm Venereol. 2007;87(1):54–61.
40.  Reitamo S, Rustin M, Harper J, et al. A 4-year follow-up study of atopic 
dermatitis therapy with 0.1% tacrolimus ointment in children and adult 
patients. Br J Dermatol. 2008;159(4):942–951.
41.  Krueger GG, Eichenfield L, Goodman JJ, et al. Pharmacokinetics of 
tacrolimus following topical application of tacrolimus ointment in adult 
and pediatric patients with moderate to severe atopic dermatitis. J Drugs 
Dermatol. 2007;6(2):185–193.
42.  Thaçi D, Reitamo S, Gonzalez Ensenat MA, et al. European Tacrolimus 
Ointment Study Group. Proactive disease management with 0.03% 
tacrolimus ointment for children with atopic dermatitis: results of a 
randomized, multicentre, comparative study. Br J Dermatol. 2008; 
159(6):1348–1356.
43.  Wollenberg A, Reitamo S, Girolomoni G, et al. European Tacrolimus 
Ointment Study Group. Proactive treatment of atopic dermatitis in 
adults with 0.1% tacrolimus ointment. Allergy. 2008;63(7):742–750.
44.  Breneman D, Fleischer AB Jr, Abramovits W, et al. Intermittent therapy 
for flare prevention and long-term disease control in stabilized atopic 
dermatitis: a randomized comparison of 3-times-weekly applica-
tions of tacrolimus ointment versus vehicle. J Am Acad Dermatol. 
2008;58(6):990–999.